FIELD: medicine, virology.
SUBSTANCE: invention relates to the vaccine strain A/17/California/04/6 (H3N2) representing a re-assortant prepared by hybridization of epidemic virus A/California/7/04 (H3N2) with the cloned cold-adopted temperature-sensitive virus A/Leningrad/134/17/K7/57 (H2N2). The strain A/Leningrad/134/17/K7/57 (H2N2) prepared for this aim is the attenuation donor, harmless for humans and its properties provides preparing re-assortant vaccine strains from newly appearing epidemic virus with guarantee. The strain A/17/California/04/6 (H3N2) shows active multiplication in developing chicken embryos at optimal temperature 33°C. The strain is characterized by temperature sensitivity and adaptation to cold. Re-assortant inherited gene encoding the basic surface viral antigen (hemagglutinin) from epidemic virus and remain seven genes encoding nonglycosylated proteins, and surface protein neuraminidase from the attenuation donor. The strain A/17/California/04/6 (H3N2) shows no reactogenicity for adult and children in intranasal administration. The invention can be used in medicine.
EFFECT: valuable medicinal properties of strain.
2 cl, 2 dwg, 6 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| VACCINE STRAIN OF FLU VIRUS A/17/CALIFORNIA/2009/38 (H1N1) FOR PROFUCTION OF LIVE INFLUENZA INTRANASAL VACCINE FOR ADULTS AND CHILDREN | 2009 |
|
RU2413765C1 |
| STRAIN OF INFLUENZA VIRUS A/17/VICTORIA/2011/89 (H3N2) FOR PRODUCTION OF LIVE INFLUENZA INTRANASAL VACCINE FOR ADULTS AND CHILDREN | 2012 |
|
RU2532844C2 |
| STRAIN OF INFLUENZA VIRUS A/17/INDIANA/11/72 (H3N2v) FOR PRODUCTION OF LIQUID INFLUENZA INTRANASAL VACCINE FOR ADULTS AND FOR CHILDREN | 2013 |
|
RU2545706C1 |
| STRAIN A/17/Texas/2012/30 (H3N2) OF INFLUEZA VIRUS FOR PRODUCING INTRANASAL LIVE INFLUENZA VACCINE FOR ADULTS AND CHILDREN | 2013 |
|
RU2563352C2 |
| VACCINE INFLUENZA VIRUS STRAIN A/17/HONGKONG/2014/8296 (H3N2) FOR PREPARING LIVE INFLUENZA INTRANASAL VACCINE FOR ADULTS AND CHILDREN | 2016 |
|
RU2606019C1 |
| REASSORTANT VACCINE STRAIN OF INFLUENZA VIRUS A/17/TASMANIA/2020/151 (H3N2) FOR PRODUCTION OF LIVE INFLUENZA INTRANASAL VACCINE FOR ADULTS AND FOR CHILDREN | 2023 |
|
RU2825672C1 |
| REASSORTANT STRAIN OF INFLUENZA VIRUS A/17/NEWCASTLE/2018/22 (H3N2) FOR THE PRODUCTION OF LIVE INTRANASAL INFLUENZA VACCINE FOR ADULTS AND CHILDREN | 2022 |
|
RU2783887C1 |
| INFLUENZA VIRUS STRAIN A/17/Anui/2013/61 (H7N9) FOR PRODUCTION OF LIVE INTRANASAL INFLUENZA VACCINE | 2013 |
|
RU2563351C2 |
| REASSORTANT STRAIN OF INFLUENZA VIRUS A/17/SOUTH AUSTRALIA/2019/122 (H3N2) FOR PRODUCTION OF LIVE INTRANASAL INFLUENZA VACCINE FOR ADULTS AND CHILDREN | 2022 |
|
RU2783877C1 |
| REASSORTANT STRAIN OF INFLUENZA VIRUS A/17/HONG KONG/2019/2573 (H3N2) FOR THE PRODUCTION OF LIVE INTRANASAL INFLUENZA VACCINE FOR ADULTS AND CHILDREN | 2022 |
|
RU2783894C1 |
